Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
2e5 of Anti-CD20 CAR-293 Cells were stained with 100 μL of 10 μg/mL of Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) and isotype control protein respectively. GFP signal was used to evaluate the binding activity (Routinely tested).
Flow cytometric analysis of Anti-CD20 CAR-293 cells staining with FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) at 1 μg/mL (1 μg/mL corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with negative control protein. FITC signal was used to evaluate the binding activity (QC tested).
Obinutuzumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 23.4 nM as determined in a SPR assay (Biacore 8K) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Rituximab biosimilar (Celltrion) | CT-P10 | Approved | Celltrion Inc | Truxima, Blitzima, Ritemvia, Rituzena | EU | Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis | Celltrion Healthcare Hungary Kft | 2017-02-17 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoproliferative Disorders; Leukemia, B-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Anemia; Microscopic Polyangiitis; Leukemia, Lymphoid; Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Details |
| Hyaluronidase/Rituximab | Approved | Genentech Inc | Rituxan Hycela | United States | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Genentech Inc | 2017-06-22 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Ublituximab | TG-1101; TGTX-1101; LFB-R603; TG-1303; EMAB-6; R-603 | Approved | Tg Therapeutics Inc | Utuxin, BRIUMVI | United States | Multiple Sclerosis | Tg Therapeutics Inc | 2022-12-28 | Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Follicular; Neuromyelitis Optica; Richter's Syndrome; Lymphoma, Mantle-Cell; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
| Rituximab Biosimilar(Shanghai Institute Of Biological Products) | SIBP-02 | Approved | Shanghai Institute Of Biological Products Co Ltd | 生利健 | Mainland China | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Shanghai Institute Of Biological Products Co Ltd | 2024-03-19 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Ibritumomab tiuxetan | IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA | Approved | Biogen Inc | Zevalin, Zavalin | United States | Lymphoma, B-Cell | Spectrum Pharmaceuticals Inc | 2002-02-19 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Zuberitamab | HS-006 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞昔 | Mainland China | Lymphoma, Large B-Cell, Diffuse | BioRay Pharmaceutical Co Ltd | 2023-05-12 | Purpura, Thrombocytopenic, Idiopathic; Nephrosis; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Glomerulonephritis, Membranous; Thrombocytopenia; Lymphoma, Non-Hodgkin | Details |
| Odronextamab | REGN-1979 | Approved | Regeneron Pharmaceuticals Inc | ORDSPONO | EU | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Regeneron Pharmaceuticals Inc | 2024-08-26 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Ofatumumab | GSK-1841157; 2F2; OMB-157; HuMax-CD2 | Approved | Genmab A/S | Arzerra, Kesimpta | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Novartis Pharma Ag | 2009-10-26 | Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
| Rituximab biosimilar (Innovent Biologics) | IBI-301 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯华, HALPRYZA | Mainland China | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Innovent Biologics(Suzhou) Co Ltd | 2020-09-30 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Burkitt Lymphoma; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
| Rituximab biosimilar (Sandoz) | GP-2013 | Approved | Sandoz | Riximyo, Rixathon | EU | Microscopic Polyangiitis; Pemphigus; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Arthritis, Rheumatoid | Sandoz Gmbh | 2017-06-15 | Lymphoma, B-Cell; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Rituximab biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Zytux | Iran | Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Aryogen Biopharma | 2014-01-01 | Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
| Rituximab biosimilar (Biosidus) | Approved | Biosidus | Argentina | Hematologic Neoplasms | Biosidus | 2013-06-01 | Hematologic Neoplasms | Details | ||
| Rituximab biosimilar (mAbxience) | RTXM-83; mAbx-02 | Approved | Mabxience Sa | Novex | Argentina | Lymphoma, Large B-Cell, Diffuse | Mabxience Sa | 2015-01-01 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Large B-Cell, Diffuse; Anemia; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic | Details |
| Rituximab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Maball, Mabura | India | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Hetero Drugs Ltd | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Rituximab biosimilar (Center of Molecular Immunology) | Approved | Center Of Molecular Immunology | CIMAbior, RituxCIM | Cuba | Lymphoma, Non-Hodgkin | null | 2017-04-01 | Lymphoma, Non-Hodgkin | Details | |
| Rituximab biosimilar (Biocad) | BCD-020 | Approved | BIOCAD JSC | Acellbia | Russian Federation | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | BIOCAD JSC | 2015-01-01 | Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Rituximab biosimilar (Reliance Life Sciences) | R-TPR-017 | Approved | Reliance Life Sciences | Toritz, RituxiRel | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | null | 2016-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
| Rituximab biosimilar (CTTQ Pharma) | TQB-2303 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Mainland China | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-05-26 | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, T-Cell | Details | ||
| Rituximab biosimilar (Shanghai Henlius Biotech) | HLX-01 | Approved | Shanghai Henlius Biotech Inc | 汉利康, AUDEXA | Mainland China | Lymphoma, Non-Hodgkin | Shanghai Henlius Biopharmaceuticals Co Ltd | 2019-02-22 | Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| Rituximab biosimilar (Amgen) | ABP-798; APB-798 | Approved | Amgen Inc | Riabni | United States | Lymphoma, Follicular; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse | Amgen Inc | 2020-12-17 | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Microscopic Polyangiitis; Anemia; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Lymphoma, B-Cell | Details |
| Rituximab biosimilar (Pfizer) | PF-05280586; PF-5280586 | Approved | Pfizer Inc | Ruxience | United States | Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Granulomatosis with Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell | Pfizer Inc | 2019-07-23 | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Richter's Syndrome; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Leukemia, Lymphoid; Microscopic Polyangiitis; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Lymphoma, B-Cell | Details |
| Obinutuzumab | RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 | Approved | Genentech Inc | Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc | 2013-11-01 | Glomerulosclerosis, Focal Segmental; Central Nervous System Lymphoma; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Nephrotic Syndrome; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lupus Nephritis; Glomerulonephritis, Membranous; Lymphoma, Large B-Cell, Diffuse; Graft vs Host Disease; Nephrosis; Leukemia, Lymphoid; Leukemia; Lymphoma, B-Cell | Details |
| Rituximab biosimilar (Probiomed) | PBO-326 | Approved | Probiomed | Kikuzubam | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | ||||
| Ripertamab | SCT-400 | Approved | SinoCelltech Ltd | Mainland China | Lymphoma, Large B-Cell, Diffuse | SinoCelltech Ltd | 2022-08-23 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details | |
| Rituximab | IDEC-102; IDEC-C2B8; RO-452294; R-105; RG-105 | Approved | Biogen Inc | MabThera, MabThera/Rituxan, 美罗华, Ristova, Rituxan | United States | Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc, Idec Pharmaceuticals Corp | 1997-11-26 | Polymyositis; Granulomatosis with Polyangiitis; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Rejection of renal transplantation; Leukemia; Hematologic Neoplasms; Myasthenia Gravis; Ocular Motility Disorders; Lymphoma, B-Cell, Marginal Zone; Diabetes Mellitus, Type 1; Liver Cirrhosis, Biliary; Peripheral Nervous System Diseases; Opsoclonus-Myoclonus Syndrome; Multiple Sclerosis, Relapsing-Remitting; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lymphoma, B-Cell; Keratoconjunctivitis Sicca; HIV Infections; Microscopic Polyangiitis; ST Elevation Myocardial Infarction; Rejection of liver transplantation; Scleritis; Myositis; Pulmonary Alveolar Proteinosis; Dermatomyositis; Stomach Neoplasms; Renal Insufficiency; Nephrosis; Hemophilia A; Immunoglobulin G4-Related Disease; Schizophrenia; Purpura; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Graft vs Host Disease; Plasmacytoma; Purpura, Thrombotic Thrombocytopenic; | Details |
| Ocrelizumab | R-1594; rhuMab 2H7; RG-1594; PRO-70769; RO-4964913 | Approved | Genentech Inc | Ocrevus | United States | Multiple Sclerosis | Genentech Inc | 2017-03-28 | Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis | Details |
| rituximab biosimilar (Zenotech) | Approved | Zenotech Laboratories | India | Lymphoma, Non-Hodgkin | Zenotech Laboratories | 2013-02-01 | Lymphoma, Non-Hodgkin | Details | ||
| Ocrelizumab/Hyaluronidase-ocsq | Approved | Genentech Inc | OCREVUS ZUNOVO | United States | Multiple Sclerosis | Genentech Inc | 2024-09-13 | Multiple Sclerosis | Details | |
| Rituximab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Mabtas | India | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Intas Biopharmaceuticals | 2013-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816; CD20-TBD | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Genmab A/S, Abbvie Inc | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Rituximab biosimilar (Dr Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Reditux, REDDITUX, Tidecron, Redditux | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | Dr.Reddy's Laboratories Ltd | 2007-01-01 | Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details | |
| Glofitamab | RG-6026; RO-7082859; RG6026-2; RO6026 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics Co Ltd | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Leukemia, B-Cell; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Details |
| Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Pancytopenia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Arthritis, Rheumatoid; Leukemia, Myelomonocytic, Chronic; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Anemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| Recombinant humanized monoclonal antibody MIL62 | MIL62 | Phase 3 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Nephrosis; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Neuromyelitis Optica; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
| Divozilimab | BCD-132 | Phase 3 Clinical | BIOCAD JSC | Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica | Details |
| Ocrelizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Multiple Sclerosis | Details | |
| Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001; B-001; B001A; B001-A; B001C; B001-C | Phase 3 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Multiple Sclerosis; Neuromyelitis Optica; Lymphoma, Non-Hodgkin; Lymphoma | Details |
| BAT-4406F | BAT-4406; BAT-4406F | Phase 3 Clinical | Bio-Thera Solutions Ltd | Neuromyelitis Optica | Details |
| Rituximab biosimilar (Nanjing Yoko Biomedical) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| Amulirafusp alfa | IMM-0306; IMC-002 | Phase 3 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
| Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details | |
| Ocrelizumab biosimilar(Amgen) | ABP 692 | Phase 3 Clinical | Amgen Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
| Ocrelizumab biosimilar (Celltrion) | CT-P53 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
| Iodine 131 tositumomab | TST/I131-TST | Phase 3 Clinical | Glaxosmithkline Plc | Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| B-007 | B-007; B007 | Phase 3 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Lymphoma, B-Cell; Myasthenia Gravis; Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin; Pemphigus | Details |
| Rituximab biosimilar(Shandong New Time Pharmaceutical) | H-02; F-007 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
| Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Hematologic Neoplasms; Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon Ltd, Vaccinex Inc | Lymphoma, Non-Hodgkin | Details |
| Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | The Southwest Hospital of AMU | Lymphoma, Large B-Cell, Diffuse | Details | |
| Rituximab biosimilar (JHL Biotech) | JHL-1101 | Phase 2 Clinical | Eden Biologics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Burkitt Lymphoma | Details |
| Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Lupus Nephritis; Primary mediastinal B cell lymphoma; Lupus Erythematosus, Systemic; Lymphoma; Scleroderma, Diffuse; Central Nervous System Lymphoma | Details |
| Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Phase 2 Clinical | Precision Biosciences Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| ELC-301 | ELC301; ELC-301 | Phase 2 Clinical | Elicera Therapeutics AB, Uppsala University | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| MBS-303 | MBS-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| bbT-369 | bbT-369 | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| GB-261 | CND261; CND-261; GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CHO-H01 | CHO-H01 | Phase 2 Clinical | Academia Sinica | Neoplasms; Lymphoma, Non-Hodgkin | Details |
| MB-CART19.1 | Phase 2 Clinical | Miltenyi Biomedicine Gmbh | Polymyositis; Lymphoma, B-Cell; Dermatomyositis; Leukemia, Lymphoid; Scleroderma, Systemic; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| AZD-5492 | AZD5492 | Phase 2 Clinical | Astrazeneca Plc | Lymphoma, B-Cell; Neoplasms; Leukemia, B-Cell | Details |
| CD19&CD20 bispecific CAR-T cells therapy(Hebei Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell | Details | |
| IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
| IMPT-314 | IMPT-314 | Phase 2 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| CD20 monoclonal antibody（The First Affiliated Hospital of Soochow University） | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Anemia, Aplastic | Details | |
| CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
| ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Leukemia; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| Rituximab Biosimilar (Istituto Giannina Gaslini) | Phase 2 Clinical | Istituto Giannina Gaslini | Nephrotic Syndrome | Details | |
| 1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| TQB-2825 | TQB-2825 | Phase 2 Clinical | Wuxi Biologics Co Ltd | Lymphoma, B-Cell, Marginal Zone; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
| CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
| JMT-601 | JMT-601 | Phase 2 Clinical | Shanghai Jmt-Bio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Prizloncabtagene autoleucel | JNJ-4496; EXP-039; C-CAR039; C-CAR-039; C CAR 039; EXP0-039; JNJ-90014496 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
| Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
| MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Imvotamab | IGM-2323 | Phase 1 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Myositis; Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis | Details |
| Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Lymphoma, Non-Hodgkin | Details |
| TRS-005 | TRS-005 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | Lymphoma, B-Cell | Details |
| Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
| Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details | |
| Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi | Details | |
| Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Bendamustine Hydrochloride/Rituximab | Phase 1 Clinical | 1globe Biomedical Co Ltd | Lymphoma, B-Cell | Details | |
| Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | Arthritis, Rheumatoid | Details |
| CD20-directed CAR-T cell therapy (Cellular Biomedicine) | C-CAR066 | Phase 1 Clinical | Cellular Biomedicine Group Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| YT-19/20 | Phase 1 Clinical | China Immunotech Co Ltd | Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
| TriCAR T-cells | Phase 1 Clinical | Children'S Hospital Los Angeles | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| ICG-132 | ICG-132 | Phase 1 Clinical | iCell Gene Therapeutics LLC | Lymphoma, B-Cell | Details |
| Dual Anti-CD19/Anti-CD20 CAR T-Cells (NCI) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| CD19/CD20 CAR-T | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| JS-203 | JS-203 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Details | |
| KITE-363 | KITE-363 | Phase 1 Clinical | Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
| ACE-1831 | ACE-1831 | Phase 1 Clinical | Acepodia Biotech Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
| CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| AcNK-Sup003 | AcNK-Sup003 | Phase 1 Clinical | SupermAb (BeiJing) Biotech Co Ltd | Lymphoma, B-Cell | Details |
| CD19/CD22-targeting CAR-T Cells therapy(Prekin Biopharmaceutical) | PRG2302; PRG-2302 | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| P-CD19 x CD20 - ALLO1 | RG6540; RG-6540 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, B-Cell | Details |
| MRG001 | MRG-001 | Phase 1 Clinical | Shanghai Miracogen Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| JWCAR-201 | JWCAR-201; JWCAR201 | Phase 1 Clinical | Shanghai Ming Ju Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | Phase 1 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma | Details | |
| LUCAR-G39D | LUCAR-G39D | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
| LUCAR-G39P | LUCAR-G39P | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, Non-Hodgkin | Details |
| Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy(Beijing Cancer Hospital) | LUCAR-20SP | Phase 1 Clinical | Beijing Cancer Hospital | Lymphoma, B-Cell | Details |
| Rituximab biosimilar (Mabscale) | Phase 1 Clinical | Mabscale LLC | Arthritis, Rheumatoid | Details | |
| JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| C-CAR168 CAR T-cell therapy (AbelZeta) | C-CAR168 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Lupus Erythematosus, Systemic; Neuromyelitis Optica; Muscular Diseases | Details |
| GF-CART01 | GF-CART01 | Phase 1 Clinical | GenomeFrontier Therapeutics TW Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Burkitt Lymphoma | Details |
| SCTB-35 | SCTB35; SCTB-35 | Phase 1 Clinical | SinoCelltech Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Pemphigus | Details | |
| IMPT-514 | IMPT-514 | Phase 1 Clinical | ImmPACT Bio USA Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Multiple Sclerosis; Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
| INT-2104 | INT-2104 | Phase 1 Clinical | Interius BioTherapeutics Inc | Lymphoma, B-Cell; Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| RO-7121932 | RO7121932; RO-7121932; RO 7121932; RG-6035 | Phase 1 Clinical | Genentech Inc | Multiple Sclerosis | Details |
| TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
| LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma | Details |
| QLP-31907 | QLP-31907; QLP31907; PSB-202 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| ADI-001 | ADI-001 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc, Adicet Bio Inc | Lymphoma, B-Cell, Marginal Zone; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Lymphoma, Large B-Cell, Diffuse; Stiff-Person Syndrome; Autoimmune Diseases; Scleroderma, Systemic; Lupus Nephritis; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details |
| CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
| LY007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
| Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
| Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Neoplasms | Details | |
| KJ-C2219 | KJ-C2219 | Clinical | CARsgen Therapeutics Holdings Ltd | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| Anti-CD20 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Rituximab biosimilar (Bioxpress) | BXT-2336; BX 2336 | Clinical | Bioxpress Therapeutics Sa | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Rituximab/Bendamustine/Cytarabine | Fondazione Italiana Linfomi Onlus | Details |
This web search service is supported by Google Inc.
A-Z
